1Brooks WM, Friedman SD, Stidley CA. Reproducibility of ^1HMRS in vivo[J]. Magn Reson Med. 1999, 41(1) :193 -197.
2Ross AT, Sachdev PS. Magnetic resonance spectroscopy in cognitive research[J]. Brain Res Rev, 2004, 44(2 -3) :83 -102.
3Costillo M, Kwock L, Mukherji SK. Clinical applications of proton MR spectroscopy[J]. AJNR,1996,17(1) :1 -15.
4Sanches RF, Crippa JA, Hallak JE, et al. Proton magnetic resonance spectroscopy of the frontal lobe in schizophrenics: a critical review of the methodology [ J ]. Rev Hosp Clin Fac Med Sao Paulo, 2004, 59(3) :145 -152.
5Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia:a systematic review and meta-analysis [ J]. Neuropsychopharmacology, 2005, 30 ( 11 ) : 1949 - 1962.
6Ohrmann P, Siegrnund A, Suslow T, et al. Cognitive impairment and in vivo metabolites in first-episode neuroleptie-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study [ J ]. J Psyehiatr Res, 2007, 41 ( 8 ) : 625 - 634.
7Galinska B, Szulc A, Tarasow E, et al. Relationship between frontal N-acetylaspartate and cognitive deficits in first-episode schizophrenia [ J ]. Med Sci Monit, 2007, 13 ( Suppl 1 ) : 11 - 16.
8Tanaka Y, Obata T, Sassa T, et al. Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction [J].Psychiatry Clin Neurosci, 2006, 60(3) :365 -372.
9Szulc A, Galinska B, Tarasow E, et al. Clinical and Nuropsychological correlates of proton magnetic resonance spectroscopy detected metabolites in brains of first-episode and schizophrenic patients [J]. Psychiatr Pol, 2003, 37(6) :977 -988.
10Wood SJ, Berger G, Velakoulis D, et al. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals[J]. Schizophr Bull, 2003, 29(4) :831 -834.
